{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T20:13:25Z","timestamp":1790108005681,"version":"4.0.1"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100006606","name":"Natural Science Foundation of Tianjin Municipality","doi-asserted-by":"publisher","award":["25JCYBJC00580"],"award-info":[{"award-number":["25JCYBJC00580"]}],"id":[{"id":"10.13039\/501100006606","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["22577092"],"award-info":[{"award-number":["22577092"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.bcp.2026.118438","type":"journal-article","created":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T14:57:59Z","timestamp":1788793079000},"page":"118438","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"P2","title":["TEAD upregulation promotes osimertinib resistance in NSCLC by recruiting YAP into the nucleus"],"prefix":"10.1016","volume":"254","author":[{"given":"Leiting","family":"Liang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenna","family":"Kong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiahui","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingjuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiajun","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qidi","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenpei","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengyang","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fuwei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhijian","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jidong","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcp.2026.118438_b0005","first-page":"277","article-title":"Cancer statistics, 2010","volume":"60","author":"Jemal","year":"2010","journal-title":"J. Clin."},{"key":"10.1016\/j.bcp.2026.118438_b0010","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.jtho.2021.11.003","article-title":"The 2021 WHO Classification of Lung Tumors Impact of Advances Since 2015","volume":"17","author":"Nicholson","year":"2021","journal-title":"J THORAC ONCOL"},{"key":"10.1016\/j.bcp.2026.118438_b0015","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1097\/JTO.0000000000000033","article-title":"A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER)","volume":"9","author":"Shi","year":"2014","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.bcp.2026.118438_b0020","doi-asserted-by":"crossref","first-page":"569","DOI":"10.3892\/ol.2021.12830","article-title":"Dacomitinib improves chemosensitivity of cisplatin-resistant human ovarian cancer cells","volume":"22","author":"Xu","year":"2021","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.bcp.2026.118438_b0025","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S1470-2045(11)70393-X","article-title":"Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial","volume":"13","author":"Rosell","year":"2012","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.bcp.2026.118438_b0030","doi-asserted-by":"crossref","first-page":"2869","DOI":"10.1200\/JCO.22.02547","article-title":"Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations","volume":"41","author":"Sequist","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bcp.2026.118438_b0035","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1158\/1535-7163.MCT-07-2232","article-title":"Antitumor activity and pharmacokinetic properties of PF-00299804, a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor","volume":"7","author":"Gonzales","year":"2008","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.bcp.2026.118438_b0040","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.lungcan.2020.07.014","article-title":"Mechanisms of osimertinib resistance and emerging treatment options","volume":"147","author":"Schmid","year":"2020","journal-title":"Lung Cancer"},{"key":"10.1016\/j.bcp.2026.118438_b0045","article-title":"Acquired resistance to third-generation EGFR-TKIs and emerging next-generation EGFR inhibitors","volume":"2","author":"Du","year":"2021","journal-title":"Innovation (Camb)"},{"key":"10.1016\/j.bcp.2026.118438_b0050","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics13091478","article-title":"Targeting BRAF activation as acquired resistance mechanism to EGFR tyrosine kinase inhibitors in EGFR-mutant non-small-cell lung cancer","volume":"13","author":"Aboubakar Nana","year":"2021","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.bcp.2026.118438_b0055","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1038\/s41416-019-0573-8","article-title":"Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer","volume":"121","author":"Leonetti","year":"2019","journal-title":"Brit. J. Cancer"},{"key":"10.1016\/j.bcp.2026.118438_b0060","doi-asserted-by":"crossref","first-page":"497","DOI":"10.18632\/genesandcancer.136","article-title":"NSCLC depend upon YAP expression and nuclear localization after acquiring resistance to EGFR inhibitors","volume":"8","author":"McGowan","year":"2017","journal-title":"Genes Cancer"},{"key":"10.1016\/j.bcp.2026.118438_b0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2021.114642","article-title":"Osimertinib-resistant NSCLC cells activate ERBB2 and YAP\/TAZ and are killed by neratinib","volume":"190","author":"Dent","year":"2021","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bcp.2026.118438_b0070","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1101\/gad.331546.119","article-title":"Induction of AP-1 by YAP\/TAZ contributes to cell proliferation and organ growth","volume":"34","author":"Koo","year":"2020","journal-title":"Gene Dev."},{"key":"10.1016\/j.bcp.2026.118438_b0075","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1038\/sj.bjc.6604774","article-title":"TEAD1 and c-Cbl are novel prostate basal cell markers that correlate with poor clinical outcome in prostate cancer","volume":"99","author":"Knight","year":"2008","journal-title":"Brit. J. Cancer"},{"key":"10.1016\/j.bcp.2026.118438_b0080","doi-asserted-by":"crossref","first-page":"6518","DOI":"10.1038\/onc.2017.257","article-title":"TEAD1\/4 exerts oncogenic role and is negatively regulated by miR-4269 in gastric tumorigenesis","volume":"36","author":"Zhou","year":"2017","journal-title":"Oncogene"},{"key":"10.1016\/j.bcp.2026.118438_b0085","doi-asserted-by":"crossref","first-page":"17685","DOI":"10.18632\/oncotarget.3779","article-title":"The interplay between TEAD4 and KLF5 promotes breast cancer partially through inhibiting the transcription of p27Kip1","volume":"6","author":"Wang","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.bcp.2026.118438_b0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2023.101791","article-title":"YAP\/TEAD-induced PRIM1 contributes to the progression and poor prognosis of gastric carcinoma","volume":"38","author":"Guo","year":"2023","journal-title":"Transl. Oncol."},{"key":"10.1016\/j.bcp.2026.118438_b0095","doi-asserted-by":"crossref","unstructured":"H.D. Huh, D.H. Kim, H. Jeong, H.W. Park, Regulation of TEAD transcription factors in cancer biology. Cells-Basel 8 (2019).","DOI":"10.3390\/cells8060600"},{"key":"10.1016\/j.bcp.2026.118438_b0100","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.gendis.2019.11.003","article-title":"The hippo tumor suppressor pathway (YAP\/TAZ\/TEAD\/MST\/LATS) and EGFR-RAS-RAF-MEK in cancer metastasis","volume":"8","author":"Zinatizadeh","year":"2021","journal-title":"Genes Dis."},{"key":"10.1016\/j.bcp.2026.118438_b0105","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1038\/ncb3464","article-title":"A ROR1-HER3-lncRNA signalling axis modulates the Hippo-YAP pathway to regulate bone metastasis","volume":"19","author":"Li","year":"2017","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.bcp.2026.118438_b0110","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1038\/s42003-024-06190-w","article-title":"Genome-wide CRISPR screens identify the YAP\/TEAD axis as a driver of persister cells in EGFR mutant lung cancer","volume":"7","author":"Pfeifer","year":"2024","journal-title":"Commun. Biol."},{"key":"10.1016\/j.bcp.2026.118438_b0115","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1038\/s41392-022-01076-x","article-title":"Liquid-liquid phase separation in tumor biology","volume":"7","author":"Tong","year":"2022","journal-title":"Signal Transduct. Tar."},{"key":"10.1016\/j.bcp.2026.118438_b0120","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/s41392-021-00678-1","article-title":"Liquid-liquid phase separation in human health and diseases","volume":"6","author":"Wang","year":"2021","journal-title":"Signal Transduct. Tar."},{"key":"10.1016\/j.bcp.2026.118438_b0125","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1038\/s41556-019-0433-z","article-title":"Phase separation of YAP reorganizes genome topology for long-term YAP target gene expression","volume":"21","author":"Cai","year":"2019","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.bcp.2026.118438_b0130","doi-asserted-by":"crossref","first-page":"4840","DOI":"10.1158\/0008-5472.CAN-20-1634","article-title":"Allosteric SHP2 inhibitor, IACS-13909, overcomes EGFR-dependent and EGFR-independent resistance mechanisms toward osimertinib","volume":"80","author":"Sun","year":"2020","journal-title":"Cancer Res."},{"key":"10.1016\/j.bcp.2026.118438_b0135","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1146\/annurev.biochem.052308.114844","article-title":"Biological and chemical approaches to diseases of proteostasis deficiency","volume":"78","author":"Powers","year":"2009","journal-title":"Annu. Rev. Biochem"},{"key":"10.1016\/j.bcp.2026.118438_b0140","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1080\/15384101.2019.1598725","article-title":"Dynamics of protein synthesis and degradation through the cell cycle","volume":"18","author":"Alber","year":"2019","journal-title":"Cell Cycle (Georgetown, Tex.)"},{"key":"10.1016\/j.bcp.2026.118438_b0145","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1038\/nrm.2017.7","article-title":"Biomolecular condensates: organizers of cellular biochemistry","volume":"18","author":"Banani","year":"2017","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.bcp.2026.118438_b0150","doi-asserted-by":"crossref","first-page":"e6020","DOI":"10.1136\/jitc-2022-006020","article-title":"YY1 complex in M2 macrophage promotes prostate cancer progression by upregulating IL-6","volume":"11","author":"Chen","year":"2023","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.bcp.2026.118438_b0155","doi-asserted-by":"crossref","first-page":"3425","DOI":"10.1016\/j.molcel.2025.08.014","article-title":"Endogenous YAP\/TAZ partitioning in TEAD condensates orchestrates the Hippo response","volume":"85","author":"Zhu","year":"2025","journal-title":"Mol. Cell"},{"key":"10.1016\/j.bcp.2026.118438_b0160","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1101\/gad.192856.112","article-title":"Genetic and pharmacological disruption of the TEAD-YAP complex suppresses the oncogenic activity of YAP","volume":"26","author":"Liu-Chittenden","year":"2012","journal-title":"Gene Dev."},{"key":"10.1016\/j.bcp.2026.118438_b0165","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1038\/nchembio.2036","article-title":"Autopalmitoylation of TEAD proteins regulates transcriptional output of the Hippo pathway","volume":"12","author":"Chan","year":"2016","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.bcp.2026.118438_b0170","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1186\/s12935-021-02056-x","article-title":"SHP2 inhibition enhances the anticancer effect of Osimertinib in EGFR T790M mutant lung adenocarcinoma by blocking CXCL8 loop mediated stemness","volume":"21","author":"Xia","year":"2021","journal-title":"Cancer Cell Int."},{"key":"10.1016\/j.bcp.2026.118438_b0175","doi-asserted-by":"crossref","unstructured":"Xi Xia, Jidong Zhu, Guo Li, Abstract 1475 Discovery of ETS-001, a highly potent allosteric SHP2 inhibitor to treat RTKRAS-driven cancers, Cancer Res 1 July 2021; 81.","DOI":"10.1158\/1538-7445.AM2021-1475"},{"key":"10.1016\/j.bcp.2026.118438_b0180","first-page":"182","article-title":"Multicenter study correlating molecular characteristics and clinical outcomes of cancer cases with patient-derived organoids","volume":"44","author":"Navarro","year":"2025","journal-title":"J. Exp. Clin. Cancer Res. CR"},{"key":"10.1016\/j.bcp.2026.118438_b0185","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s12967-025-07112-y","article-title":"Patient-derived organoids predict responses to chemotherapy and PARP inhibitors in advanced ovarian cancer","volume":"24","author":"Wang","year":"2026","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.bcp.2026.118438_b0190","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2022.105707","article-title":"Identification of Small-molecule YAP-TEAD inhibitors by High-throughput docking for the Treatment of colorectal cancer","volume":"122","author":"Li","year":"2022","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bcp.2026.118438_b0195","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2025.217467","article-title":"Targeting YAP\/TAZ-TEAD signaling as a therapeutic approach in head and neck squamous cell carcinoma","volume":"612","author":"Sato","year":"2025","journal-title":"Cancer Lett."},{"key":"10.1016\/j.bcp.2026.118438_b0200","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1038\/s43018-024-00754-9","article-title":"Direct and selective pharmacological disruption of the YAP-TEAD interface by IAG933 inhibits Hippo-dependent and RAS-MAPK-altered cancers","volume":"5","author":"Chapeau","year":"2024","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.bcp.2026.118438_b0205","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/nrclinonc.2017.166","article-title":"Tumour heterogeneity and resistance to cancer therapies","volume":"15","author":"Dagogo-Jack","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.bcp.2026.118438_b0210","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/s41586-019-1730-1","article-title":"A view on drug resistance in cancer","volume":"575","author":"Vasan","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.bcp.2026.118438_b0215","doi-asserted-by":"crossref","first-page":"3019","DOI":"10.1158\/1078-0432.CCR-24-3691","article-title":"JAB-3312, a potent allosteric SHP2 inhibitor that enhances the efficacy of RTK\/RAS\/MAPK and PD-1 blockade therapies","volume":"31","author":"Kang","year":"2025","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bcp.2026.118438_b0220","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.cellsig.2007.10.002","article-title":"The molecular functions of Shp2 in the Ras\/Mitogen-activated protein kinase (ERK1\/2) pathway","volume":"20","author":"Dance","year":"2008","journal-title":"Cell. Signal."},{"key":"10.1016\/j.bcp.2026.118438_b0225","doi-asserted-by":"crossref","first-page":"204","DOI":"10.7150\/ijbs.22955","article-title":"Combination strategies using EGFR-TKi in NSCLC therapy: learning from the gap between pre-clinical results and clinical outcomes","volume":"14","author":"Yang","year":"2018","journal-title":"Int. J. Biol. Sci."}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000629522600777X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000629522600777X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T19:51:00Z","timestamp":1790106660000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S000629522600777X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":45,"alternative-id":["S000629522600777X"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2026.118438","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"TEAD upregulation promotes osimertinib resistance in NSCLC by recruiting YAP into the nucleus","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2026.118438","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"118438"}}